Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Patel
  ACTRN12620000454976		 zincplaceboCOVID 19 hospitalizedhigh
15/18 inconclusive
    Mobarak (DISCOVER)
          IRCT20200624047908N1    		 RCTsofosbuvir and daclatasvirplaceboCOVID 19 hospitalizedNA
    		541/542 inconclusive
    • inconclusive 1 % increase in hospital discharge (PE)
    Mobarak S (DISCOVER)
          IRCT20200624047908N    		 RCTsofosbuvir and daclatasvirplaceboCOVID 19 hospitalizedsome concern
    		541/542 inconclusive
    • inconclusive 3 % decrease in recovery (PE) with a moderate degree of certainty due to some concern in risk of bias
    Gonzalez (IVER)
          NCT04391127    		 RCTivermectinplaceboCOVID 19 hospitalizedsome concern
    		36/37 inconclusive
      NIH NIAID ACTT-1
              NCT04280705      		 RCTremdesivirplaceboCOVID 19 hospitalizedsome concern
      		541/521 suggested
      • suggested 45 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 29 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 35 % increase in clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias

      COVID 19 all comers meta-analysis

      EPIC-SR unpublished
              NCT05011513      		 RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 all comersNA
      		-/- inconclusive

        COVID-19 mild to moderate meta-analysis

        Fontanesi
                  NCT04348409        		 RCTnitazoxanideplaceboCOVID-19 mild to moderateNA
        		25/25 no results
          Holubar M
                      NCT04346628          		 RCTfavipiravir placeboCOVID-19 mild to moderateNA
          		75/74 inconclusive
          • inconclusive 24 % decrease in viral clearance ,viral clearance (time to event analysis only) (PE)
          Kirti
                      CTRI/2020/08/027225          		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
          		57/58 inconclusive
          • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
          RIVET-COV (Mohan) (12mg and 24mg)
                      CTRI/2020/06/026001          		 RCTivermectinplaceboCOVID-19 mild to moderatehigh
          		104/52 inconclusive
          • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
          Shenoy S
                      NCT04529499          		 RCTfavipiravir placeboCOVID-19 mild to moderatehigh
          		175/178 inconclusive
          • inconclusive 1 % decrease in clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
          Shinkai
                      JapicCTI-205238          		 RCTfavipiravir placeboCOVID-19 mild to moderatesome concern
          		107/49 safety concern
          • inconclusive 40 % increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 18.5-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
          Silva
                      NCT04463264          		 RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
          		33/13 inconclusive
            Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
            		48/24 suggested
            • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
            Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
            Chaccour
                          NCT04390022            		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
            		12/12 inconclusive
            • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
            Rocco
                          NCT04552483            		 RCTnitazoxanideplaceboCOVID-19 mild to moderatehigh
            		238/237 inconclusive
            • inconclusive 19 % decrease in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias

            COVID-19 severe or critically meta-analysis

            CAP-China (Wang et al.)
                          NCT04257656            		 RCTremdesivirplaceboCOVID-19 severe or criticallylow
            		158/79 inconclusive
            • inconclusive 23 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a high degree of certainty due to low risk of bias
            2 studies excluded by filtering options (0 RCT / 2 OBS)

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons